Navigation Links
Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
Date:11/12/2009

LAIYANG, China, Nov. 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that the Company's management will present at the upcoming Brean Murray, Carret & Co. 2009 China Growth Conference.

    Date:           November 19, 2009
    Time:           10:40 a.m. - 11:15 a.m. EST
    Presenter:      Ms. Elsa Sung, CFO
    Location:       The Millennium Broadway Hotel
                    New York, NY

The Brean Murray, Carret & Co. 2009 China Growth Conference is a two-day conference (November 19-20, 2009) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. Jiangbo's management will be available for 1x1 meetings before and after the Company's presentation.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:   http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE Jiangbo Pharmaceuticals, Inc.


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin
2. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
4. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
5. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
6. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
7. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
9. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
10. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
11. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology: